Evidence‑Based Recommendations for Dexmethylphenidate and Methylphenidate in Adults with ADHD and Comorbid Depression

Dosing Equivalence

• Dexmethylphenidate provides therapeutic effect at approximately half the dose of racemic methylphenidate because it contains only the pharmacologically active d‑enantiomer, eliminating the inactive l‑enantiomer. 1

First‑Line Pharmacologic Choice

• In adults who have ADHD together with non‑severe depression (no psychosis, suicidality, or marked neurovegetative signs), a stimulant trial should be initiated first to allow rapid assessment of ADHD symptom response. [2][3]
• Both methylphenidate (5–20 mg three times daily) and dexmethylphenidate extended‑release (10–40 mg once daily) are endorsed as first‑line treatment options for adult ADHD. 2

Impact on Depressive Symptoms

• Effective control of ADHD symptoms reduces ADHD‑related morbidity and can lead to a substantial improvement in co‑occurring depressive symptoms. 2

Management of Persistent Depression

• If depressive symptoms persist after adequate ADHD symptom control, the recommended next steps are to add evidence‑based psychotherapy (e.g., cognitive‑behavioral therapy or interpersonal therapy) or initiate an antidepressant, rather than switching the ADHD stimulant. [2][3]